European Medicines Agency’s Committee for Medicinal Products for Human Use recommends marketing authorisation for idarucizumab (Praxbind), a specific reversal agent for dabigatran
On 24 September 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing... Read More
Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.
Eerenberg ES, Middeldorp S, Levi M, Lensing AW, Buller HR
J Thromb Haemost 2015;13:1590-1596.
Review by D. Faraoni
Tranexamic acid for preventing postpartum haemorrhage.
Novikova N, Hofmeyr GJ, Cluver C
Cochrane Database Syst Rev 2015;6:CD007872.
Review by B. J. Hunt
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.